Biotech Stocks Technical Report – Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma

Biotech Stocks Technical Report – Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma

LONDON, January 28, 2015 /PRNewswire/ –Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Agenus Inc. (NASDAQ: AGEN), Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research report on Halozyme Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Halozyme%20Therapeutics&d=28-Jan-2015&s=HALO. On Tuesday, January 27, 2015, the NASDAQ Composite ended at 4,681.50, down 1.89%, the Dow Jones Industrial Average declined 1.65%, to finish the day at 17,387.21, and the S&P 500 closed at 2,029.55, down 1.34%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 818.80, down 0.75%, while the index has advanced 8.40% in the previous three months. Register for your complimentary reports at the links given below. ;

Halozyme Therapeutics Inc.’s stock edged 0.28% higher, to close the day at $14.48. The stock recorded a trading volume of 1.20 million shares, below its three months average volume of 1.75 million shares. The stock oscillated between $14.10 and $14.80 during the session. Over the last one month and over the past three months, Halozyme Therapeutics Inc.’s shares have surged 50.52% and 56.71%, respectively. However, the stock has lost 8.76% in the previous one year. The company’s shares closed above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $10.23 is above its 200-day moving average of $9.29. Additionally, Halozyme Therapeutics Inc. has a Relative Strength Index (RSI) of 70.19. Sign up and read the free notes on HALO at:

http://get.Investor-Edge.com/pdf/?c=Halozyme%20Therapeutics&d=28-Jan-2015&s=HALO

On Tuesday, shares in Agenus Inc. recorded a trading volume of 1.14 million shares, lower than its three months average volume of 1.81 million shares. The stock ended the day at $5.26, which was 0.19% above its previous day’s closing of $5.25, and registered an intraday range of $5.13 and $5.39. Agenus Inc.’s shares have rallied 27.36% in the last one month, 73.03% in the last three months and 70.23% in the past one year. The company’s stock closed above its 50-day and 200-day moving averages of $3.85 and $3.25, respectively. Furthermore, shares of Agenus Inc. have an RSI of 59.52. The complimentary notes on AGEN can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Agenus&d=28-Jan-2015&s=AGEN

Biogen Idec Inc.’s stock declined 1.26%, to close Tuesday’s session at $357.89, after oscillating between $357.13 and $364.76. The stock recorded a trading volume of 1.44 million shares, below its three months average volume of 1.74 million shares. Over the last one month and the previous three months, Biogen Idec Inc.’s shares have advanced 4.52% and 11.85%, respectively. Additionally, the stock has gained 20.15% in the last one year. The company’s shares closed above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $335.52 is above its 200-day moving average of $321.39. Further, Biogen Idec Inc.’s stock traded at a PE ratio of 34.61 and has an RSI of 59.27. Register for free on Investor-Edge and access the latest research on BIIB at:

http://get.Investor-Edge.com/pdf/?c=Biogen%20Idec&d=28-Jan-2015&s=BIIB

ACADIA Pharmaceuticals Inc.’s stock finished Tuesday’s session 1.80% lower at $31.70. A total of 1.65 million shares were traded, which was above its three months average volume of 1.24 million shares. The stock moved between $31.61 and $32.17 during the session. Over the last three months and the previous one year, ACADIA Pharmaceuticals Inc.’s shares have surged 17.23% and 41.20%, respectively. However, the stock has lost 0.09% in the past one month. The company’s shares closed above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $31.04 is greater than its 200-day moving average of $24.95. ACADIA Pharmaceuticals Inc.’s stock has an RSI of 51.34. The complete research on ACAD is available for free at:

http://get.Investor-Edge.com/pdf/?c=ACADIA%20Pharma&d=28-Jan-2015&s=ACAD

On Tuesday, shares in Peregrine Pharmaceuticals Inc. fluctuated between $1.32 and $1.36 before ending the session 1.48% lower at $1.33. The stock reported a trading volume of 0.71 million shares, below its three months average volume of 0.90 million shares. Peregrine Pharmaceuticals Inc.’s shares have declined 0.75% in the previous three trading sessions, 8.28% in the last one month and 20.83% in the last one year. The company’s stock closed below its 50-day and 200-day moving averages of $1.42 and $1.59, respectively. Moreover, shares of Peregrine Pharmaceuticals Inc. have an RSI of 42.76. Free in depth research on PPHM is available at:

http://get.Investor-Edge.com/pdf/?c=Peregrine%20Pharma&d=28-Jan-2015&s=PPHM

About Investor-Edge.com ;

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That’s where Investor-Edge comes in. We provide a single unified platform for investors’ to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR’S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors’ package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

Originally posted here: 

Biotech Stocks Technical Report – Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma

Share this post

Comments (0)